bluebird bio
60 Binney St
Cambridge
MA
02142
United States
Tel: 339-499-9300
Website: http://www.bluebirdbio.com/
Email: info@bluebirdbio.com
About bluebird bio
bluebird bio is leading the gene therapy revolution. We have nearly 15 years of scientific and clinical experience at the forefront of gene therapy, with deep expertise in rare diseases and immuno-oncology, a proven scientific and lentiviral-based manufacturing platform, and a complementary set of tools such as gene editing.
We are a patient- and purpose-driven, product-oriented organization. Our diverse flock of bluebirds is united by a singular focus: a passionate commitment to changing the lives of patients and supporting each other on this journey. At bluebird bio, we will work like crazy with a never-give-up, little-but-mighty attitude, as exemplified by our namesake, the Eastern Bluebird.
we are always innovating, never stopping and never giving up.
Stock symbol: BLUE
Stock exchange: NASDAQ
Our birds are constantly reminded of the difference they can make on the lives of patients and in the lives of their fellow birds – no matter what their title may be. Whether it’s running a successful experiment in the lab, developing a new and efficient process for your team, being an inspiring mentor for those around you, or always being a friendly face in the morning, we can all make an impact and we can all make a difference. How will you Make Your Mark?
436 articles with bluebird bio
-
bluebird bio Appoints Two New Members to its Board of Directors Wendy Dixon, Ph.D., and David Schenkein, M.D.
5/6/2013
-
bluebird bio Forms Cancer Drug Partnership With Celgene Corporation
3/21/2013
-
bluebird bio to Present at the 31st Annual J.P. Morgan Healthcare Conference
1/3/2013
-
bluebird bio to Present at UBS Global Life Sciences Conference
9/13/2012
-
bluebird bio Snags $60 Million From Existing VC's and Newcomers Like Shire plc
7/25/2012
-
bluebird bio Receives U.S. and European Orphan Drug Designation for Novel Gene Therapy to Treat Adrenoleukodystrophy
6/19/2012
-
John Maraganore, Ph.D., Joins the bluebird bio Board of Directors
5/31/2012
-
bluebird bio to Present at Cowen and Company 32nd Annual Health Care Conference
2/28/2012
-
bluebird bio Appoints David Davidson, M.D., as Chief Medical Officer
2/16/2012
-
bluebird bio to Present at the Leerink Swann and Company 2012 Global Healthcare Conference
2/9/2012
-
genOway Acquires Worldwide Exclusive License for RMCE Technology From bluebird bio for Genetically Modified Rodents
7/12/2011
-
bluebird bio Adds Biotech Industry Veterans to Management Team and Board
5/16/2011
-
bluebird bio Secures Additional $30 Million in Financing; ARCH Venture Partners Joins Investor Team
4/20/2011
-
bluebird bio Appoints World Leading Experts to Inaugural Scientific Advisory Board
3/21/2011
-
bluebird bio Appoints Alexandre P. LeBeaut, M.D., as Chief Medical Officer
3/17/2011
-
bluebird bio Awarded up to $4.2 Million from the French Muscular Dystrophy Association for Continued Development of Gene Therapy for Beta-Thalassemia and Sickle Cell Anemia
3/16/2011